Skip to content
Screener

ADMA Biologics ADMA ADMA Bio Manufacturing — Total Assets

Other segment segments

Plasma Collection Centers
$21.86M-25.0%

Similar metrics at other companies

The Greenbrier Companies logo
GBXManufacturing — Total Assets
$1.95B-5.9%
Twin Disc logo
TWINManufacturing — Total Assets
$506.29M+2.2%
ProFrac Holding Corp. logo
ACDCManufacturing — Total Assets
$467.2M+6.1%
CNT
CNTNClinical Stage Bio Technology — Total Assets
$1.66M—
Acacia Research logo
ACTGManufacturing Operations — Total Assets
$122.06M-9.7%
Amplitech Group, Inc. logo
AMPGManufacturing And Engineering — Total Assets
$23.65M+5.6%

Other financials

Income statement

See full
Revenue$124.4M+2.0%
Gross profit$86.3M+28.3%
Operating income$52.4M+22.5%
Net income$37.8M+10.5%
EPS (diluted)$0.16+14.3%

Balance sheet

See full
Cash & equivalents$136.0M+50.7%
Total debt$203.9M+1,855%
Total equity$408.2M+2.5%
Total assets$684.2M+22.5%

Cash flow

See full
Operating cash flow$29.5M+39.7%
CapEx$2.3M-6.9%
Free cash flow$27.3M+45.8%

Valuation

See full
Market cap$2.25B-49.1%
Enterprise value$2.32B-46.6%
P/E13.3×-7.9×
P/S4.4×-4.9×

Profitability

See full
Gross margin64.7%+11.7pp
Operating margin43.8%+11.0pp
Net margin33%-11.1pp
FCF margin22.7%+8.9pp

Returns & leverage

See full
Return on equity41.9%-29.3pp
Debt / equity0.5×+0.5×
Current ratio7×+1.6×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:Assets.

The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:16 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001140361-26-031445
(in thousands)ADMA Bio ManufacturingPlasma Collection CentersTotal
Other income (expense), net(20)150130
Income (loss) before taxes64,010(707)63,303
Expenditures for additions to long-lived assets2,256-2,256
Total assets453,53821,864475,402
Reconciliation of revenues:
Segment revenue$124,360
License revenue35
Consolidated revenues$124,395

Item 1. Financial Statements.

FAQ

What is ADMA Biologics's ADMA bio manufacturing — total assets?
ADMA Biologics (ADMA) reported ADMA bio manufacturing — total assets of $453.54M in Q2 2026.
How has ADMA Biologics's ADMA bio manufacturing — total assets changed year-over-year?
ADMA Biologics's ADMA bio manufacturing — total assets increased by 23.2% year-over-year, from $368.23M to $453.54M.
What is the long-term trend for ADMA Biologics's ADMA bio manufacturing — total assets?
Over 4 years (2021 to 2025), ADMA Biologics's ADMA bio manufacturing — total assets has grown at a 20.9% compound annual growth rate (CAGR), from $723.75M to $1.54B.
What does ADMA bio manufacturing — total assets mean?
This metric represents the total economic resources controlled by the BioManufacturing segment, including inventory, manufacturing equipment, and specialized facilities. It provides a snapshot of the asset base dedicated to the production and distribution of plasma-derived biologics. Analyzing this figure helps assess the segment's operational scale and the efficiency with which it utilizes its asset base to generate revenue.

Ask your AI about ADMA Biologics's adma bio manufacturing — total assets.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude